Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SynaVir
Birmingham, Alabama, USAsynavir.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SynaVir is a pre-clinical stage biotechnology company dedicated to the development of advanced antiviral therapeutics. Founded by researchers from the University of Alabama at Birmingham, the company utilizes a proprietary platform to engineer synthetic decoy receptors that neutralize viruses by mimicking the host cell's natural entry points. This approach is designed to be "variant-proof," as it targets the fundamental binding mechanisms that viruses must maintain to remain infectious. SynaVir's current pipeline focuses on high-impact respiratory pathogens, including SARS-CoV-2 and influenza. The company aims to provide a robust defense against both current and emerging viral threats through its innovative protein engineering technology.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant proteinProtein
- Industry
- Biotech
02
Partnerships
University of Alabama at Birmingham
Beyond the preview
Go deeper on SynaVir.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynaVir.